Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN493370 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Protein Phosphatase 2, Catalytic Subunit, alpha Isozyme (PPP2CA) (Catalytic Subunit) antibody
- Antibody type
- Polyclonal
- Antigen
- The PP2Ac-selective antibodies were generated against purified human kidney protein Phosphatase 2A catalytic subunit.
- Description
- Affinity Chromatography over immobilized antigen
- Reactivity
- Human, Mouse, Rat, Chicken/Avian
- Host
- Rabbit
- Epitope
- Catalytic Subunit
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 1-1.25 mg/mL
- Storage
- Store the antibody undiluted (in aliquots) at-20°C.
- Handling
- Avoid repeated freezing and thawing.
Submitted references PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
The formation and activity of PP2A holoenzymes do not depend on the isoform of the catalytic subunit.
The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
[Not Available].
Moon EY, Lerner A
Blood 2003 May 15;101(10):4122-30
Blood 2003 May 15;101(10):4122-30
The formation and activity of PP2A holoenzymes do not depend on the isoform of the catalytic subunit.
Zhou J, Pham HT, Walter G
The Journal of biological chemistry 2003 Mar 7;278(10):8617-22
The Journal of biological chemistry 2003 Mar 7;278(10):8617-22
The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A, Ackland SP, Gardiner E, Walkom CC, Sakoff JA
Anti-cancer drug design 2001 Dec;16(6):291-303
Anti-cancer drug design 2001 Dec;16(6):291-303
[Not Available].
ABEGG E
Ciba-Zeitschrift 1948 May;10(112):4122-8
Ciba-Zeitschrift 1948 May;10(112):4122-8
No comments: Submit comment
No validations: Submit validation data